It is licensed for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W135 and Y. The carrier protein used in Menveo, CRM197, is a naturally occurring nontoxic mutant of diphtheria toxin.
A pivotal randomised phase III trial conducted in the US compared Menveo to the US-licensed conjugated quadrivalent vaccine Menactra in 3539 healthy individuals aged 11–55 years.
Separate analyses showed Menveo to be superior to Menactra in adults (19–55 years of age) and adolescents (11–18 years of age) in terms of seroresponse rates (serogroup-specific serum bactericidal activity) 28 days after vaccination. Indeed, seroresponse rates were generally higher with Menveo than with Menactra.
Quadrivalent meningococcal vaccination should be considered in high-risk individuals travelling to the ‘meningitis belt' in sub-Saharan Africa and is compulsory for pilgrims and seasonal workers going to Mecca on the Hajj/Umra pilgrimage.
Further information: Novartis Vaccines